Novartis's 'step change' Cosentyx likely to compete well after NICE nod
This article was originally published in Scrip
Executive Summary
Novartis' psoriasis treatment Cosentyx (secukinumab) looks set to win a funding recommendation from NICE, the health technology appraisal institute for England and Wales. The yes hinges on a confidential patient access scheme that offers the drug at a discount to the NHS.